Search Within

Eric J Sherman

  1. "Molecular Pharmacology and Chemistry Program Faculty"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (3)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (7)
  2. Department of Medicine (7)
  3. Division of Subspecialty Medicine (7)
  4. Endocrinology (7)
  5. GSK Faculty (7)
  6. Head and Neck Service (7)

More Groups

People
  1. James Fagin (7)
  2. Ronald Ghossein (6)
  3. Alan Ho (5)
  4. David Pfister (5)
  5. Keith Pentlow (5)
  6. Ravinder Grewal (5)

More People

Years
  1. 2022 (2)
  2. 2019 (1)
  3. 2013 (3)
  4. 2012 (1)
Publications
  1. Journal of Clinical Oncology (2)
  2. Cancer Discovery (1)
  3. Cancer Research (1)
  4. Journal of Clinical Endocrinology and Metabolism (1)
  5. New England Journal of Medicine (1)
  6. Thyroid (1)
Publishers
  1. American Association for Cancer Research (2)
  2. American Society of Clinical Oncology (2)
  3. Mary Ann Liebert, Inc (1)
  4. Massachusetts Medical Society (1)
  5. Oxford University Press (1)

Results (7)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 2 of trametinib plus radioiodine in RAS-mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446)
    Meeting Abstract

    Burman, B.; Tuttle, R. M.; Grewal, R. K.; Sherman, E. J.; Baxi, S. S.; Boucai, L.; Sabra, M.; Fish, S.; Pentlow, K. S.; Haque, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ERBB3 monoclonal antibody CDX-3379: Results of a pilot clinical trial
    Journal Article

    Tchekmedyian, V.; Dunn, L.; Sherman, E.; Baxi, S. S.; Grewal, R. K.; Larson, S. M.; Pentlow, K. S.; Haque, S.; Tuttle, R. M.; Sabra, M. M.; more...
    Thyroid (2022)

    Fulltext@MSK | Save
  • Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers
    Journal Article

    Dunn, L. A.; Sherman, E. J.; Baxi, S. S.; Tchekmedyian, V.; Grewal, R. K.; Larson, S. M.; Pentlow, K. S.; Haque, S.; Tuttle, R. M.; Sabra, M. M.; more...
    Journal of Clinical Endocrinology and Metabolism (2019)

    Fulltext@MSK | Save
  • Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas
    Meeting Abstract

    Montero-Conde, C.; Ruiz-Llorente, S.; Domínguez, J. M.; Knauf, J. A.; Viale, A.; Sherman, E. J.; Ryder, M.; Ghossein, R. A.; Rosen, N.; Fagin, J. A.
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF -mutant thyroid carcinomas
    Journal Article

    Montero-Conde, C.; Ruiz-Llorente, S.; Domínguez, J. M.; Knauf, J. A.; Viale, A.; Sherman, E. J.; Ryder, M.; Ghossein, R. A.; Rosen, N.; Fagin, J. A.
    Cancer Discovery (2013)

    Fulltext@MSK | Save
  • Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer
    Journal Article

    Ho, A. L.; Grewal, R. K.; Leboeuf, R.; Sherman, E. J.; Pfister, D. G.; Deandreis, D.; Pentlow, K. S.; Zanzonico, P. B.; Haque, S.; Gavane, S.; more...
    New England Journal of Medicine (2013)

    Fulltext@MSK | Save
  • Reacquisition of RAI uptake in RAI-refractory metastatic thyroid cancers by pretreatment with the MEK inhibitor selumetinib
    Meeting Abstract

    Ho, A. L.; Leboeuf, R.; Grewal, R. K.; Sherman, E. J.; Deandreis, D.; Pentlow, K. S.; Tuttle, R. M.; Fury, M. G.; Ricarte-Filho, J. C. M.; Pfister, D. G.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save